Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 114186686 | 11418668 | 6 | F | 20150401 | 20160922 | 20150826 | 20160927 | EXP | CA-ROCHE-1626339 | ROCHE | 57.73 | YR | F | Y | 0.00000 | 20160927 | CN | CA | CA |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 114186686 | 11418668 | 1 | PS | XOLAIR | OMALIZUMAB | 1 | Subcutaneous | U | S0002F,S0003B | 103976 | 150 | MG | SOLUTION FOR INJECTION | ||||||
| 114186686 | 11418668 | 2 | SS | XOLAIR | OMALIZUMAB | 1 | Subcutaneous | U | S0002F,S0003B | 103976 | 150 | MG | SOLUTION FOR INJECTION | ||||||
| 114186686 | 11418668 | 3 | SS | XOLAIR | OMALIZUMAB | 1 | Subcutaneous | U | S0002F,S0003B | 103976 | SOLUTION FOR INJECTION | ||||||||
| 114186686 | 11418668 | 4 | SS | XOLAIR | OMALIZUMAB | 1 | Subcutaneous | U | S0002F,S0003B | 103976 | SOLUTION FOR INJECTION | ||||||||
| 114186686 | 11418668 | 5 | SS | XOLAIR | OMALIZUMAB | 1 | Subcutaneous | U | S0002F,S0003B | 103976 | SOLUTION FOR INJECTION | ||||||||
| 114186686 | 11418668 | 6 | SS | XOLAIR | OMALIZUMAB | 1 | Subcutaneous | U | S0002F,S0003B | 103976 | SOLUTION FOR INJECTION | ||||||||
| 114186686 | 11418668 | 7 | SS | XOLAIR | OMALIZUMAB | 1 | Subcutaneous | U | S0002F,S0003B | 103976 | SOLUTION FOR INJECTION | ||||||||
| 114186686 | 11418668 | 8 | SS | XOLAIR | OMALIZUMAB | 1 | Subcutaneous | U | S0002F,S0003B | 103976 | SOLUTION FOR INJECTION | ||||||||
| 114186686 | 11418668 | 9 | SS | XOLAIR | OMALIZUMAB | 1 | Subcutaneous | U | S0002F,S0003B | 103976 | SOLUTION FOR INJECTION |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 114186686 | 11418668 | 1 | Asthma |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 114186686 | 11418668 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 114186686 | 11418668 | Blood pressure increased | |
| 114186686 | 11418668 | Fatigue | |
| 114186686 | 11418668 | Headache | |
| 114186686 | 11418668 | Injection site pain | |
| 114186686 | 11418668 | Stress |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 114186686 | 11418668 | 1 | 20150401 | 0 | ||
| 114186686 | 11418668 | 2 | 20150625 | 0 | ||
| 114186686 | 11418668 | 3 | 20150820 | 0 | ||
| 114186686 | 11418668 | 4 | 20150917 | 0 | ||
| 114186686 | 11418668 | 5 | 20160602 | 0 | ||
| 114186686 | 11418668 | 6 | 20160630 | 0 | ||
| 114186686 | 11418668 | 7 | 20160728 | 0 | ||
| 114186686 | 11418668 | 8 | 20160825 | 0 | ||
| 114186686 | 11418668 | 9 | 20160922 | 0 |